Edding Genor Group Holdings Limited
Research Edding Genor Group Holdings Limited (6998.HK) on Bullrun: market cap HKD 3.24B, P/E 10.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6998.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 3.24B
- P/E10.3
- Financial periodFY2025
- RevenueCNY 2.49B
- Revenue growth-2.3%
- Net incomeCNY 399.26M
- Free cash flowCNY 404.05M
- Gross margin68.2%
Valuation Snapshot
latest market cap is HKD 3.24B; P/E is 10.3.
Peer valuation comparison
Latest P/E is 10.28x versus a Healthcare sector median of 21.69x (52.6% below).
Latest P/E is 10.28x versus a China median of 16.26x (36.8% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 2.49B | CNY 399.26M | CNY 404.05M | 68.2% | n/a | CNY 1.05B | CNY 1.49B | CNY 3.85B |
| FY2024 | CNY 2.55B | CNY 387.89M | CNY 728.38M | 67.4% | 0.19 | CNY 111.70M | CNY 2.03B | CNY 2.41B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.24B | 10.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Edding Genor Group Holdings Limited
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Edding Genor Group Holdings Limited's market cap?
Edding Genor Group Holdings Limited's market capitalization is HKD 3.24B.
What is Edding Genor Group Holdings Limited's P/E ratio?
Edding Genor Group Holdings Limited's price-to-earnings (P/E) ratio is 10.3.
What does Edding Genor Group Holdings Limited do?
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial.